1. Faster-Acting Insulins

3. Program Overview

4. Biochemical and Physiological Actions of Insulin

5. Insulin and Glucose Profiles: Healthy Subjects

6. Exogenous vs Endogenous Insulin

7. Exogenous vs Endogenous Insulin (cont)

8. Therapeutic Objectives in Diabetes Management

9. Factors Affecting Insulin Absorption

10. Insulin Uptake From SC Tissue: Advantages of Rapid-Acting Insulins

11. Meta-Analysis: Better Postprandial BG Control With Insulin Aspart vs RHI

12. Insulin Aspart Significantly Reduced the Rate of Severe Nocturnal Hypoglycemia in T1DM

13. CGM Analysis

14. Need for Faster-Acting Insulins

15. PPG as a Glycemic Target

16. Agents for Control of PPG

17. Advantages of Rapid-Acting Analogues vs RHI

18. Rapid-Acting Insulin Analogues and PPG Control: Current Challenges

19. Guidelines for the Management of Postprandial Hyperglycemia: T1DM

20. ADA Recommendations: Combination Injectable Therapy in T2DM

21. AACE Algorithm for Intensifying Insulin

22. Faster Aspart: A New Formulation of Insulin Aspart

23. Onset of Exposure of Faster Aspart: Pooled Analysis of 6 Studies in Patients With T1DM

24. Early Exposure of Faster Aspart:
Early Exposure of Faster Aspart:* Pooled Analysis of 6 Studies in Patients With T1DM

25. Faster Aspart: Onset and "Offset" of Exposure*

26. Onset® 3: Study Design

27. Onset® 3: Mean HbA1c Over Time

28. Onset® 3: 8-Point SMPG Profile at Week 18

29. Onset® 2*: Mean Change in HbA1c Over Time

30. Onset® 2: PPG Increment (Meal Test) at Week 26

31. Ultra-Rapid Insulin Lispro U100 in Patients With T2DM

32. PK Differences: Ultra-Rapid Insulin Lispro U100 vs Insulin Lispro in T2DM

33. PD Differences: Ultra-Rapid Insulin Lispro U100 vs Insulin Lispro in T2DM

34. Onset® 1: Study Design

35. Onset® 1: Mean HbA1c Change From Baseline

36. Onset® 1: PPG Increment at Week 26

37. Onset® 1: Safety

38. Ultra-Rapid Formulation of Lispro U100 in Patients With T1DM

39. PK/PD Differences: Ultra-Rapid Insulin Lispro U100 vs Insulin Lispro in T1DM

40. Onset, Offset, and Overall Exposure of Faster Aspart vs Insulin Aspart in CSII

41. Better PPG Control in CSII With Faster Aspart*

42. Role of Faster Aspart in the Management of Patients With Diabetes

43. Concluding Remarks